# PegIntron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (P04498/MK-4031-278)

> **NCT00371761** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 25 (actual)

## Conditions studied

- Hepatitis B, Chronic (CHB)

## Interventions

- **BIOLOGICAL:** Pegylated interferon alfa-2b (PegIntron)
- **DRUG:** Adefovir dipivoxil (adefovir)

## Key facts

- **NCT ID:** NCT00371761
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2017-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00371761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00371761, "PegIntron Versus Adefovir in the Treatment of Chronic Hepatitis B (CHB) e Antigen Positive Patients in Taiwan (P04498/MK-4031-278)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00371761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*